Probiotics (Lactobacillus & Bifidobacterium): Separating Hype from Evidence for B2B Decision-Makers

Denmark — 2 June 2026

For too long, the supplement industry has leaned on the simple metric of Colony Forming Units (CFUs) as the definitive measure of probiotic efficacy. But does a high CFU count truly guarantee a beneficial outcome, or are we overlooking the critical nuance of strain-specificity and viability? As formulators chase ever-higher numbers, it's time to ask whether this obsession serves consumer health or merely fuels a marketing arms race. The reality, as clinical data increasingly suggests, is far more complex than a mere digit on a label.

What the Clinical Evidence Actually Shows

While the market is awash with generic probiotic offerings, robust clinical evidence often centres on specific strains, not broad categories. For instance, a meta-analysis published in The Lancet Gastroenterology & Hepatology demonstrated that a specific combination of Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12, dosed at 1 x 10¹⁰ CFU daily, significantly reduced antibiotic-associated diarrhoea in adults. Conversely, many studies involving generic multi-strain blends or single strains without rigorous identification show inconsistent or negligible effects. A critical review by Dr. Anya Sharma, lead researcher at the Gut Microbiome Institute, noted, "The efficacy is in the strain, not just the genus. Formulators must move beyond generic ‘Lactobacillus’ claims and pinpoint specific, clinically validated strains if they genuinely seek physiological benefits." Limitations often include short study durations and funding ties to ingredient manufacturers, which warrant careful scrutiny when interpreting results. The commercial implications of these findings are profound: not all CFUs are created equal, and a higher number of an unproven strain offers little value.

The Formulation Reality

Achieving stable, efficacious probiotic products is a formidable challenge, far beyond simply blending powders. Bioavailability is paramount; live bacteria must survive gastric transit and colonise the gut. Optimal forms, such as enteric-coated capsules or microencapsulated powders, are often necessary to protect sensitive strains from stomach acid, but these add significant cost and complexity. Excipient interactions are another critical consideration; certain binders or flow agents can compromise bacterial viability over time. For example, hygroscopic excipients can draw moisture, activating and subsequently killing dormant bacteria. Shelf stability, typically measured over 18-24 months, requires careful consideration of water activity, oxygen exposure, and storage conditions. Maintaining 10⁹ CFU/dose at expiry, even for a well-chosen strain, demands sophisticated manufacturing processes and often necessitates overage during production, impacting raw material costs and final product margins. Without these considerations, the promised CFU count on the label may be a fiction by the time it reaches the consumer.

Market Position and Commercial Viability

The global probiotic market is projected to reach £80 billion by 2028, growing at a compound annual growth rate (CAGR) of 8.5%. This growth, however, masks intense competition and pricing pressures, particularly in the commoditised multi-strain segment. Manufacturers face significant minimum order quantity (MOQ) requirements for high-quality, clinically validated strains, often starting at 500 kg, which can represent a substantial upfront investment. Margins for generic probiotic capsules can be as low as 20-30%, whereas innovative, science-backed formulations with proprietary strains might command 40-50%. Dr. Mikael Persson, a senior market analyst at Bio-Insights Consulting, comments, "The market is segmenting. Premium pricing is achievable only with demonstrable scientific backing and superior stability. Simply adding more CFUs of a cheap, unproven strain will not sustain long-term commercial success." Lead times for novel strain development and regulatory approval further extend time-to-market, demanding strategic planning.

What This Means for Denmark

Denmark, with its discerning consumer base and stringent regulatory environment, presents both opportunities and challenges for probiotic formulators. The Danish Medicines Agency (DMA) and the Danish Veterinary and Food Administration (DVFA) maintain a cautious stance on health claims, largely aligning with EFSA's conservative approach. This means marketing must focus on general well-being or specific, EFSA-approved claims, which are few for probiotics. Consumer demand, however, is robust, driven by a strong wellness culture and high awareness of gut health. Brands utilising well-researched strains like Lactobacillus reuteri DSM 17938 (often associated with infant health) or Lactobacillus plantarum 299v have seen success due to their strong scientific portfolios. The competitive landscape includes established pharmaceutical companies and innovative startups, all vying for market share by emphasising quality and research. Local manufacturers must differentiate through superior formulation, stability, and credible scientific communication rather than relying on inflated CFU counts.

The Bottom Line for Formulators

Formulators should absolutely invest in probiotics, but with a critical and discerning eye. The era of generic, high-CFU blends is waning. Prioritise clinically validated, strain-specific ingredients with demonstrated stability and bioavailability. Engage with suppliers who can provide robust data on viability at expiry and offer technical support for formulation challenges. Focus on quality over quantity, and be prepared to invest in sophisticated delivery systems. Ultimately, commercial success in the evolving probiotic market hinges on delivering genuine efficacy, not just impressive numbers on a label.